Novo Nordisk announced Phase 2a trial results for monlunabant. The trial demonstrated a weight reduction of 7.1 kg with a 10 mg daily dose compared to placebo.

Fortress Biotech shares are trading lower by 20% Friday afternoon. The company announced the pricing of a $8 million registered direct offering and concurrent private placements.

In this morning’s readout from Novo's phase 2 trial of monlunabant in 243 people with obesity and metabolic syndrome, it ...

September 20, 2024 (Investorideas.com Newswire) Investorideas.com, a global news source and expert investing resource, announces today's roundup of stocks to watch in the mining, energy, cleantech and ...

Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through ...

Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental obesity pill monlunabant came in below market expectations.

This Peninsula biotech company started as a way to find a cancer drug for a co-founder's father. It now layoffs show it’s ...

Investorideas.com ( a go-to investing platform covering cannabis stocks releases an industry snapshot looking at the battle against dangerous drugs, including fentanyl, featuring Greenlane Holdings, ...

FN Media Group News Commentary - Breast cancer is an illness in which the breast cells get uncontrollably large. The type of breast cancer depends on which cells in the breast become cancerous. Cancer ...

Ginkgo Bioworks is pivoting: Once a synthetic biology darling, the flailing company has now turned to AI-driven protein ...

Recursion Pharmaceuticals has an exciting approach to developing therapies. The company recently reported positive phase 2 ...

Sana Biotechnology Inc (SANA) stock saw a modest uptick, ending the day at $4.62 which represents a slight increase of $0.33 or 7.69% from the prior close of $4.29. The stock opened at $4.47 and ...